CN1803191A - 一种高强度聚焦超声治疗用助剂及其筛选方法 - Google Patents
一种高强度聚焦超声治疗用助剂及其筛选方法 Download PDFInfo
- Publication number
- CN1803191A CN1803191A CNA2005100003458A CN200510000345A CN1803191A CN 1803191 A CN1803191 A CN 1803191A CN A2005100003458 A CNA2005100003458 A CN A2005100003458A CN 200510000345 A CN200510000345 A CN 200510000345A CN 1803191 A CN1803191 A CN 1803191A
- Authority
- CN
- China
- Prior art keywords
- eef
- hifu
- auxiliary agent
- treatment
- measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012752 auxiliary agent Substances 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000012216 screening Methods 0.000 title abstract description 5
- 238000009210 therapy by ultrasound Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 238000005259 measurement Methods 0.000 claims abstract description 24
- 238000002604 ultrasonography Methods 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 12
- 230000008021 deposition Effects 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims description 39
- 239000007924 injection Substances 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 28
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 26
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 24
- 239000007789 gas Substances 0.000 claims description 23
- 210000003462 vein Anatomy 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 21
- 239000000839 emulsion Substances 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 11
- 238000010253 intravenous injection Methods 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 239000012620 biological material Substances 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 6
- 239000011162 core material Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- -1 Fluorine carbon hydrocarbon Chemical class 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003570 air Substances 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical compound [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 abstract description 6
- 206010019695 Hepatic neoplasm Diseases 0.000 abstract description 5
- 208000014018 liver neoplasm Diseases 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 37
- 241000283973 Oryctolagus cuniculus Species 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 31
- 210000004185 liver Anatomy 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 230000001225 therapeutic effect Effects 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 230000006378 damage Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 206010028851 Necrosis Diseases 0.000 description 18
- 230000037396 body weight Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 12
- 239000000787 lecithin Substances 0.000 description 12
- 235000010445 lecithin Nutrition 0.000 description 12
- 229940067606 lecithin Drugs 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003995 emulsifying agent Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000011587 new zealand white rabbit Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 235000005687 corn oil Nutrition 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000007872 degassing Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 101000915639 Homo sapiens Zinc finger protein 470 Proteins 0.000 description 4
- 241000029523 Procapra gutturosa Species 0.000 description 4
- 102100029038 Zinc finger protein 470 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 229960004692 perflenapent Drugs 0.000 description 4
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RIQRGMUSBYGDBL-UHFFFAOYSA-N 1,1,1,2,2,3,4,5,5,5-decafluoropentane Chemical compound FC(F)(F)C(F)C(F)C(F)(F)C(F)(F)F RIQRGMUSBYGDBL-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical class CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229960004624 perflexane Drugs 0.000 description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 229920006197 POE laurate Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
Abstract
Description
实施例I-1-2 | 实施例I-1-3 | 实施例I-1-4 | |
注射用大豆油在助剂中的含量(W/V) | 10% | 20% | 10% |
注射用大豆油用量 | 100g | 200g | 100g |
注射用卵磷脂用量 | 12g | 12g | 12g |
注射用甘油用量 | 22g | 22g | 16.7g |
注射用水(加至) | 1000ml | 1000ml | 1000ml |
pH值约为 | 8 | 8 | 8 |
非连续相的粒径 | 0.1~2μm | 1~5μm | 0.5~2μm |
渗透压(mosm/千克水) | 300 | 350 | 310 |
能量MJ(kcal) | 4.6(1100) | 8.4(2000) | 12.6(3000) |
实施例I-2-3 | 实施例I-2-4 | 实施例I-2-5 | 实施例I-2-6 | |
芯材料 | 2%(V/V)全氟戊烷 | 5%(V/V)全氟己烷 | 10%(V/V)全氟己烷 | 10%(V/V)二氢十氟戊烷 |
卵磷脂用量 | 1%(W/V) | 2%(W/V) | 2%(W/V) | 2%(W/V) |
甘油用量 | 1%(W/V) | 1%(W/V) | 1%(W/V) | 1%(W/V) |
Pluronic F-68用量 | 5%(W/V) | 3%(W/V) | 5%(W/V) | 5%(W/V) |
蒸馏水(加至) | 1000ml | 1000ml | 1000ml | 1000ml |
pH值约为 | 6.98 | 7.01 | 6.99 | 7.00 |
非连续相粒径 | 0.5~2μm | 0.5~2μm | 0.1~2μm | 1~2μm |
实施例II-3 | 实施例II-4 | 实施例II-5 | |
纳米级HAP用量(粒径) | 25g/L(1~500nm) | 25g/L(1~500nm) | 50g/L(1~500nm) |
卵磷脂用量 | 0.3g | 0.3g | 0.6g |
CMC-Na用量 | 0.3g | 0.6g | 0.3g |
注射用甘油用量 | 1ml | 1ml | 2ml |
蒸馏水(加至) | 100ml | 100ml | 100ml |
pH值约为 | 5.0 | 5.0 | 5.0 |
非连续相的粒径 | 10~1000nm | 10~1000nm | 10~1000nm |
渗透压(mosm/千克水) | 275(等渗) | 275(等渗) | 275(等渗) |
A组 | B组 | 合计 | P值 | |
对照叶实验叶P值 | 7.09±4.112.73±1.64<0.00l | 6.67±3.133.43±2.07<0.00l | 6.87±3.603.10±1.89<0.001 | >0.5*>0.5* |
组别 | N | EEF( x±s)(J/mm3) |
正常组实验组 | 3030 | 31.05±2.687.16±1.38* |
n | 损伤时间 | |||
3s | 6s | 9s | ||
对照组实验组P值 | 2130 | 0.2749±0.24090.1177±0.0609<0.01 | 0.1783±0.07330.1367±0.0613<0.05 | 0.1846±0.08960.1463±0.069>0.05 |
组别 | 辐照点数 | V(mm3) | EEF(J/mm3) |
对照组第一给药组第二给药组 | 244517 | 582.50±353.931281.56±884.561525.63±1007.46 | 7.39±4.992.71±1.292.25±1.61 |
药物 | 用量 | n | V/mm3 | EEF |
对照组HAP组1HAP组2HAP组3 | 2ml/kg50mg/kg100mg/kg150mg/kg | 30302521 | 95.3±21.6153.1±41.8223.2±55.1287.7±47.9 | 0.39±0.090.24±0.050.19±0.010.13±0.00 |
用药后时间 | n | 平均治疗时间(s) | 平均焦域体积(mm3) | 平均EEF |
对照组 | 16 | 15 | 546.67 | 7.39±4.99 |
24小时48小时72小时168小时 | 57172726 | 15.8815.616.1515 | 1291.561525.631153.26920 | 2.68±1.292.32±1.613.28±1.352.51±0.87 |
组别 | EEF(J/mm3) |
对照组实验组 | 12.83±10.992.70±1.29* |
Claims (20)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100003458A CN100427142C (zh) | 2005-01-10 | 2005-01-10 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
US11/794,928 US20090117052A1 (en) | 2005-01-10 | 2005-08-30 | Enhancement agent for high intensity focused ultrasound treatment and method for screening the same |
CA002593638A CA2593638A1 (en) | 2005-01-10 | 2005-08-31 | Enhancement agent for high intensity focused ultrasound treatment and method for screening the same |
RU2007127667/14A RU2363494C2 (ru) | 2005-01-10 | 2005-08-31 | Средство, усиливающее эффект обработки фокусированным ультразвуком высокой интенсивности, и способ скрининга данного средства |
BRPI0518499-1A BRPI0518499A2 (pt) | 2005-01-10 | 2005-08-31 | adjuvante para ultra-som focalizado de alta intensidade e mÉtodo de seleÇço |
JP2007549780A JP4773458B2 (ja) | 2005-01-10 | 2005-08-31 | 高密度焦点式超音波療法のための増強剤および同剤のスクリーニングの方法 |
AU2005324271A AU2005324271A1 (en) | 2005-01-10 | 2005-08-31 | A high-intensity focused ultrasound adjuvant and the screening method thereof |
PCT/CN2005/001367 WO2006072198A1 (fr) | 2005-01-10 | 2005-08-31 | Adjuvant pour un traitement par ultrasons focalises a haute intensite et son procede de depistage |
KR1020077015751A KR20070095937A (ko) | 2005-01-10 | 2005-08-31 | 고강도 집속형 초음파 처치용 강화제 및 이를 스크리닝하는 방법 |
EP05781912A EP1842560A4 (en) | 2005-01-10 | 2005-08-31 | ADJUVANT FOR HIGH INTENSITY FOCUSED ULTRASONIC TREATMENT AND ITS SCREENING METHOD |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100003458A CN100427142C (zh) | 2005-01-10 | 2005-01-10 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1803191A true CN1803191A (zh) | 2006-07-19 |
CN100427142C CN100427142C (zh) | 2008-10-22 |
Family
ID=36647406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100003458A Active CN100427142C (zh) | 2005-01-10 | 2005-01-10 | 一种高强度聚焦超声治疗用助剂及其筛选方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090117052A1 (zh) |
EP (1) | EP1842560A4 (zh) |
JP (1) | JP4773458B2 (zh) |
KR (1) | KR20070095937A (zh) |
CN (1) | CN100427142C (zh) |
AU (1) | AU2005324271A1 (zh) |
BR (1) | BRPI0518499A2 (zh) |
CA (1) | CA2593638A1 (zh) |
RU (1) | RU2363494C2 (zh) |
WO (1) | WO2006072198A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112004479A (zh) * | 2018-04-20 | 2020-11-27 | 泰拉克利昂公司 | 用于定位肢体内的静脉的方法和装置 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100574810C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用质粒类助剂及其应用 |
KR101292939B1 (ko) * | 2010-12-31 | 2013-08-02 | 삼성전자주식회사 | 엠알유도 고강도집속초음파 치료 및 진단용 인지질 나노입자 및 이의 제조방법 |
RU2472545C1 (ru) * | 2011-07-28 | 2013-01-20 | Вера Александровна Хохлова | Способ неинвазивного разрушения расположенных за костями грудной клетки биологических тканей |
WO2013167654A1 (en) * | 2012-05-09 | 2013-11-14 | Sinvent As | Ultrasound contact fluid |
ES2951663T3 (es) * | 2013-09-27 | 2023-10-24 | Exact Therapeutics As | Administración de fármacos |
IT201900025303A1 (it) | 2019-12-23 | 2021-06-23 | Sergio Casciaro | Dispositivo e metodo per la classificazione tissutale |
IT201900025306A1 (it) | 2019-12-23 | 2021-06-23 | Imedicals S R L | Dispositivo e metodo per il monitoraggio di trattamenti hifu |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5832829A (ja) * | 1981-08-22 | 1983-02-25 | Green Cross Corp:The | 血管造影剤 |
US4767610A (en) * | 1984-10-19 | 1988-08-30 | The Regents Of The University Of California | Method for detecting abnormal cell masses in animals |
US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
CA1335714C (en) * | 1989-07-05 | 1995-05-30 | David M. Long, Jr. | Fluorocarbon emulsions having saturated phospholipid emulsifiers |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5344640A (en) * | 1991-10-22 | 1994-09-06 | Mallinckrodt Medical, Inc. | Preparation of apatite particles for medical diagnostic imaging |
IL113139A0 (en) * | 1994-03-28 | 1995-06-29 | Nycomed Imaging As | Diagnostic compositions comprising imaging agents encapsulated in liposomes |
KR100500334B1 (ko) * | 1996-02-19 | 2005-09-09 | 아머샴 헬스 에이에스 | 조영제또는그와관련된개선 |
JPH10130169A (ja) * | 1997-06-26 | 1998-05-19 | Imarx Pharmaceut Corp | 超音波処理用組成物 |
US6254852B1 (en) * | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
CN1224590C (zh) * | 2002-05-22 | 2005-10-26 | 吉林大学 | 一种复合磁性粒子的制备方法 |
CN100574810C (zh) * | 2005-01-10 | 2009-12-30 | 重庆海扶(Hifu)技术有限公司 | 一种高强度聚焦超声治疗用质粒类助剂及其应用 |
-
2005
- 2005-01-10 CN CNB2005100003458A patent/CN100427142C/zh active Active
- 2005-08-30 US US11/794,928 patent/US20090117052A1/en not_active Abandoned
- 2005-08-31 RU RU2007127667/14A patent/RU2363494C2/ru active
- 2005-08-31 KR KR1020077015751A patent/KR20070095937A/ko not_active Application Discontinuation
- 2005-08-31 WO PCT/CN2005/001367 patent/WO2006072198A1/zh not_active Application Discontinuation
- 2005-08-31 AU AU2005324271A patent/AU2005324271A1/en not_active Abandoned
- 2005-08-31 CA CA002593638A patent/CA2593638A1/en not_active Abandoned
- 2005-08-31 BR BRPI0518499-1A patent/BRPI0518499A2/pt not_active IP Right Cessation
- 2005-08-31 EP EP05781912A patent/EP1842560A4/en not_active Withdrawn
- 2005-08-31 JP JP2007549780A patent/JP4773458B2/ja active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112004479A (zh) * | 2018-04-20 | 2020-11-27 | 泰拉克利昂公司 | 用于定位肢体内的静脉的方法和装置 |
Also Published As
Publication number | Publication date |
---|---|
JP4773458B2 (ja) | 2011-09-14 |
KR20070095937A (ko) | 2007-10-01 |
US20090117052A1 (en) | 2009-05-07 |
AU2005324271A1 (en) | 2006-07-13 |
JP2008526785A (ja) | 2008-07-24 |
RU2007127667A (ru) | 2009-01-27 |
EP1842560A4 (en) | 2008-03-19 |
BRPI0518499A2 (pt) | 2008-11-25 |
WO2006072198A1 (fr) | 2006-07-13 |
RU2363494C2 (ru) | 2009-08-10 |
EP1842560A1 (en) | 2007-10-10 |
CN100427142C (zh) | 2008-10-22 |
CA2593638A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100427142C (zh) | 一种高强度聚焦超声治疗用助剂及其筛选方法 | |
Choi et al. | Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo | |
RU2388492C2 (ru) | Фторуглеродный эмульсионный активатор для высокоинтенсивной фокусированной ультразвуковой терапии и его применение | |
CN100574811C (zh) | 一种高强度聚焦超声治疗用微粒类助剂及其应用 | |
CN100574810C (zh) | 一种高强度聚焦超声治疗用质粒类助剂及其应用 | |
ter Haar | Ultrasound bio-effects and safety considerations | |
CN1298400C (zh) | 超声微泡造影剂用于形成毛细血管栓塞的医疗装置 | |
CN1958093A (zh) | 光敏剂作为高强度聚焦超声增敏剂的应用 | |
Patel | Development of a Co-loaded Lonidamine and Paclitaxel Ultrasound Contrast Agent for Treatment of Multi-Drug Resistant Tumors | |
Chen et al. | Ultrasound-Triggered on Demand Lidocaine Release Relieves Postoperative Pain | |
McCreery et al. | Therapeutic Applications of Targeted Microbubbles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER NAME: CHONGQING HAIFU (HIFU) TECHNOLOGY CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 401121 No. 1 Pine Road, man Town, Chongqing, Yubei District Patentee after: Chongqing Haifu Medical Technology Co., Ltd. Address before: 401121 No. 1 Pine Road, man Town, Chongqing, Yubei District Patentee before: Haifu (HIFU) Technology Co., Ltd., Chongqing |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 359, jingdongfang Avenue, Beibei District, Chongqing 400714 Patentee after: Chongqing Haifu Medical Technology Co.,Ltd. Address before: 401121 No. 1 Pine Road, man Town, Chongqing, Yubei District Patentee before: Chongqing Haifu Medical Technology Co.,Ltd. |